Ondine Biomedical Inc. announces that Mater Hospital, North Sydney, a private hospital in New South Wales, has become the first Australian hospital to start using its light-activated antimicrobial Steriwave® technology to prevent the spread of hospital-acquired infections (HAIs). Mater Hospital, located in North Sydney and founded in 1906, is part of St. Vincent's Health Australia Group, Australia's largest not-for-profit provider of health and aged care services.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.24 GBX | -3.47% | -3.47% | -17.26% |
06-10 | Transcript : Ondine Biomedical Inc., 2023 Earnings Call, Jun 10, 2024 | |
06-07 | Ondine Biomedical loss narrows as revenue soars 88% in 2023 | AN |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-17.26% | 26.39M | |
-6.01% | 180B | |
-2.95% | 105B | |
-4.54% | 67.27B | |
-6.09% | 46.34B | |
+14.28% | 46.22B | |
+4.14% | 40.1B | |
+19.36% | 30.92B | |
+12.05% | 24.22B | |
-4.56% | 24.48B |
- Stock Market
- Equities
- OBI Stock
- News Ondine Biomedical Inc.
- Mater Hospital, to Use Ondine Biomedical's Award-Winning Light-Activated Antimicrobial Technology